趋化因子受体CCR6及CCR7在喉鳞状细胞癌中表达的研究

Expression of CCR6 and CCR7 in laryngeal squamous cell carcinoma

目的:探讨趋化因子受体CCR6、CCR7及其配体CCL20、CCL19/CCL21在喉鳞状细胞癌(LSCC)中的表达及其与临床病理特征的相关性。方法:以50例LSCC患者的肿瘤组织、癌旁组织、颈清扫淋巴结、外周血为研究对象,采用实时定量逆转录聚合酶链反应(real-timeqRT-PCR)技术、免疫组织化学技术及流式细胞术检测趋化因子受体CCR6、CCR7及其配体(CCL20、CCL19/CCL21)的表达。结果:real-timeqRT-PCR检测发现LSCC肿瘤组织中CCR6、CCR7及CCL19/CCL21mRNA的表达量低于癌旁组织(P<0.05),CCL20mRNA的表达量高于癌旁组织(P<0.05);免疫组织化学检测发现LSCC肿瘤组织及转移淋巴结均有CCR6和CCR7的表达,且伴颈淋巴结转移的LSCC组织CCR6、CCR7的表达高于不伴颈淋巴结转移组织,差异有统计学意义(P<0.05);流式细胞术检测发现,LSCC患者外周血CD4+CCR6+T细胞占外周血单个核细胞的比例显著高于正常对照组(P<0.05),而CD4+CCR7+T细胞的比例则显著低于正常对照组(P<0.05)。结论:趋化因子受体CCR6、CCR7在LSCC组织、转移淋巴结及外周血中表达,与LSCC的发展、浸润、颈部淋巴结转移有关。

Objective：To evaluate the expressions of chemokine receptor 6（CCR6）,chemokine receptor 7（CCR7） and their ligands（CCL20,CCL19/CCL21）in laryngeal squmaous cell carcinoma（LSCC）,and then explore their correlation with the clinicopathological features of LSCC.Method：Blood samples,fresh specimens of LSCC and paired adjacent tissues were collected.The expressions of CCR6,CCR7 and their ligands CCL20,CCL19/CCL21mRNA as well as the protein CCR6,CCR7 were detected by real-time qRT-PCR and IHC respectively.Flow cytometry was also used to investigate CCR6,CCR7 expressed on PBMC.Result：The relative expression levels of CCR6,CCR7,CCL19and CCL21mRNA in tumor tissue was significantly higher than that of adjacent tissues（P0.05）,while the relative expression level of CCL20mRNA in tumor tissue were significantly lower than that of adjacent tissues（P0.05）.IHC confirmed the expression of protein CCR6and CCR7 in both tumor tissue and metastatic LN and the expression levels of protein CCR6,CCR7 were higher in the cases with lymphatic metastasis than that of those without lymphatic metastasis（P0.05）.FCM showed the percentage of CD4＋CCR6＋T cells of LSCC was significantly higher than that of normal control（P0.05）,while that of CD4＋CCR7＋T cells was significantly lower（P0.05）.Conclusion：CCR6and CCR7 are expressed in tumor situ,metastatic LN and PBMC,and might exert a potential role in LSCC development.